Paul Emery (University of Leeds, UK) told delegates that both doses of peresolimab showed significant superiority to placebo for reduction in DAS28-CRP score during the first 12-week period of the study.

Paul Emery and colleagues, from the University of Leeds in the UK, explain that musculoskeletal complaints make up around 30% of general practice consultations in England and it can be difficult to manage the large number of referrals to rheumatology services.

This preclinical period may be predicted by the presence of anti-CCP3 antibodies, suggesting that identifying patients with musculoskeletal symptoms who are positive for both anti-CCP2 and anti-CCP3 but with no clinical synovitis “may represent the optimal ‘window of opportunity’ for intervention to prevent joint disease,” write Paul Emery (University of Leeds, UK) and co-authors in Rheumatology .

Paul Emery (Leeds Musculoskeletal Biomedical Research Centre, UK) and colleagues analyzed the results of four placebo- and active-controlled studies among patients with active RA who were naïve to conventional synthetic (cs)DMARDs (RA-BEGIN) or had an inadequate response to previous treatment with methotrexate (RA-BEAM), csDMARDs (RA-BUILD), or biologic DMARDs (RA-BEACON) to characterize the impact of temporary baricitinib interruptions on symptoms and efficacy.

The PREDICTRA trial, by Paul Emery (University of Leeds, UK) and colleagues, also found that not all patients who flare during tapering can regain remission when adalimumab is reinstated.

Paul Emery and John Fitton present the case of a patient who has responded to treatment with the JAK inhibitor tofacitinib as her sixth-line targeted therapy for biologic-refractory rheumatoid arthritis.

Paul Emery and John Fitton present the case of a patient who has responded to treatment with the JAK inhibitor tofacitinib as her sixth-line targeted therapy for biologic-refractory rheumatoid arthritis.

“This pivotal study confirms the importance of rapid referral clinics and immediate therapy,” say Paul Emery and Laurence Duquenne, both from the University of Leeds in the UK, in an editorial accompanying the research published in The Lancet Rheumatology .

Previous results from the phase III study demonstrated equivalence of SB4 and etanercept at 24 weeks among patients with moderate-to-severe disease despite methotrexate treatment, say Paul Emery (University of Leeds, UK) and fellow researchers.